Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

NCT03027609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Pseudomonas Aeruginosa Pneumonia

Interventions

DRUG: AR-105
DRUG: Placebo

Sponsor

Aridis Pharmaceuticals, Inc.